At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
TARA ArTara Therapeutics, Inc.
Closed Christmas Day 12-24 13:00:00 EST
5.17
+0.02
+0.39%
盘后5.05
-0.12-2.26%
16:55 EST
High5.20Low5.05Vol310.05K
Open5.15D1 Closing5.15Amplitude2.91%
Mkt Cap177.43MTradable Cap150.80MTotal Shares34.32M
T/O1.59MT/O Rate1.06%Tradable Shares29.17M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Protara Therapeutics Closes $100 Million Securities Offering
MT Newswires Live  ·  12-12
Protara Therapeutics Closes $100 Million Securities Offering
BUZZ-U.S. STOCKS ON THE MOVE-CoreCivic, Alphabet, Vail Resorts
Reuters  ·  12-11
BUZZ-U.S. STOCKS ON THE MOVE-CoreCivic, Alphabet, Vail Resorts
BUZZ-U.S. STOCKS ON THE MOVE-Boeing, Alaska Air, Centene
Reuters  ·  12-10
BUZZ-U.S. STOCKS ON THE MOVE-Boeing, Alaska Air, Centene
Protara Therapeutics Prices $100 Million Offering of Shares, Pre-Funded Warrants
MT Newswires Live  ·  12-10
Protara Therapeutics Prices $100 Million Offering of Shares, Pre-Funded Warrants
BRIEF-Protara Prices Public Offering Of 13.69 Mln Shares At $6.25 Per Share
Reuters  ·  12-10
BRIEF-Protara Prices Public Offering Of 13.69 Mln Shares At $6.25 Per Share
Protara Announces Pricing of $100 Million Public Offering
THOMSON REUTERS  ·  12-10
Protara Announces Pricing of $100 Million Public Offering
Protara Therapeutics Inc - Prices Public Offering of 13.69 Mln Shares at $6.25 per Share
THOMSON REUTERS  ·  12-10
Protara Therapeutics Inc - Prices Public Offering of 13.69 Mln Shares at $6.25 per Share
Protara Therapeutics Launches Common Stock Offering; Shares Fall After Hours
MT Newswires Live  ·  12-10
Protara Therapeutics Launches Common Stock Offering; Shares Fall After Hours
BUZZ-Protara Therapeutics slides after unveiling stock deal
Reuters  ·  12-10
BUZZ-Protara Therapeutics slides after unveiling stock deal
Protara Therapeutics Shares Down 8.2% After the Bell; Announces Proposed Public Offering
THOMSON REUTERS  ·  12-10
Protara Therapeutics Shares Down 8.2% After the Bell; Announces Proposed Public Offering
Protara Therapeutics announces common stock offering, no amount given
TIPRANKS  ·  12-10
Protara Therapeutics announces common stock offering, no amount given
BRIEF-Protara Announces Proposed Public Offering
Reuters  ·  12-10
BRIEF-Protara Announces Proposed Public Offering
Protara Announces Proposed Public Offering
THOMSON REUTERS  ·  12-10
Protara Announces Proposed Public Offering
Protara Therapeutics Inc - to Use Proceeds to Fund Clinical Development of Tara-002
THOMSON REUTERS  ·  12-10
Protara Therapeutics Inc - to Use Proceeds to Fund Clinical Development of Tara-002
Press Release: Protara Announces Proposed Public Offering
Dow Jones  ·  12-10
Press Release: Protara Announces Proposed Public Offering
TARA Stock Soars on Superior Efficacy of Bladder Cancer Cell Therapy
Zacks  ·  12-06
TARA Stock Soars on Superior Efficacy of Bladder Cancer Cell Therapy
Protara Therapeutics Price Target Maintained With a $23.00/Share by HC Wainwright & Co.
Dow Jones  ·  12-06
Protara Therapeutics Price Target Maintained With a $23.00/Share by HC Wainwright & Co.
Promising Efficacy of TARA-002 Positions Protara Therapeutics as a Compelling Buy for HR-NMIBC Treatment
TIPRANKS  ·  12-06
Promising Efficacy of TARA-002 Positions Protara Therapeutics as a Compelling Buy for HR-NMIBC Treatment
Sector Update: Health Care Stocks Retreat Late Afternoon
MT Newswires  ·  12-06
Sector Update: Health Care Stocks Retreat Late Afternoon
Crude Oil Edges Lower; US Initial Jobless Claims Increase
Benzinga  ·  12-06
Crude Oil Edges Lower; US Initial Jobless Claims Increase
No data available

Introduction

Company Name.
ArTara Therapeutics, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.
Issue price:
--